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Background: In Scotland, a national HPV immunisation programme began in 2008 for 12- to 13-year olds, with a catch-up
campaign from 2008 to 2011 for those under the age of 18. To monitor the impact of HPV immunisation on cervical disease at the
population level, a programme of national surveillance was established.
Methods:We analysed colposcopy data from a cohort of women born between 1988 and 1992 who entered the Scottish Cervical
Screening Programme (SCSP) and were aged 20–21 in 2008–2012.
Results: By linking datasets from the SCSP and colposcopy services, we observed a significant reduction in diagnoses of cervical
intraepithelial neoplasia 1 (CIN 1; RR 0.71, 95% CI 0.58 to 0.87; P¼ 0.0008), CIN 2 (RR 0.5, 95% CI 0.4 to 0.63; Po0.0001) and CIN 3
(RR 0.45, 95% CI 0.35 to 0.58; Po0.0001) for women who received three doses of vaccine compared with unvaccinated women.
Conclusions: To our knowledge, this is one of the first studies to show a reduction of low- and high-grade CIN associated with
high uptake of the HPV bivalent vaccine at the population level. These data are very encouraging for countries that have achieved
high HPV vaccine uptake.
In the UK, cervical cancer is the second most common cancer in
women under 35 years (Cancer research UK, 2010). Human
papillomavirus (HPV) types 16 and 18 are known to be essential
for the development of at least 70% of cervical cancers (Smith et al,
2007) but may contribute in excess of 80% of cervical cancers in
Scotland (Cuschieri et al, 2010). The prophylactic bivalent vaccine
prevents infection with HPV types 16 and 18 and has been shown
to induce strong and sustained neutralising antibody responses
that prevent cervical HPV 16 and 18 infection and confer
protection against consequent viral-induced cervical intraepithelial
neoplasia (CIN; Paavonen et al, 2009). The vaccine may also afford
immunological cross-protection against other high-risk oncogenic
HPV types that are phylogenetically related to HPV 16 and 18,
including HPV 31, 33 and 45 (Malagon et al, 2012; Kavanagh et al,
2014).
The quadrivalent HPV vaccine has been provided in Australia
through the national HPV vaccination programme since April
2007. Early indications from the HPV vaccination programme
suggest that there has been a decrease in high-grade cervical
cytological abnormalities (coded as CIN of grade 2 or worse or
CGIN) of the cervix in girls younger than 18 years (Brotherton
et al, 2011). Although the study did not directly link pathology
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results with immunisation status, it provided evidence that high
uptake of the HPV vaccine (B70%) was temporally correlated with
a decrease in cervical cancer precursors at the population level.
Since 2008, school-based uptake of bivalent HPV vaccine in girls
aged 12–13 in Scotland has been impressive, with vaccine uptake
sustained at levels 490% (National Health Service (NHS)
Information Services Division, 2011; Sinka et al, 2014). Further-
more, a 3-year (from September 2008 to 2011) catch-up campaign
offered vaccination to all girls aged 13–17, with uptake recorded
between 80% and 30% in younger and older girls at age of
vaccination, respectively (NHS Information Services Division,
2012). In order to estimate vaccine impact it is important to
ascertain the effect of the vaccination programme on the whole
population, with particular focus on the age group where these
changes will be initially observed. In Scotland cervical screening is
offered 3-yearly to all women aged 20–60 years. Therefore it is one
of the few countries in the world able to detect an early impact of
the vaccine through population-based surveillance.
Scotland has a population of 5.2 million and almost all care is
provided by the NHS. Preventive health programmes operate
population registers based on birth and patient care registration
systems with a common unique person identifier. One of the major
strengths of Scottish health data is the ability to perform robust
data linkage in a national population, using Community Health
Index (CHI; Bhopal et al, 2012). In this study, we have used such
linkage to complete preliminary analysis of the impact of the
bivalent vaccine on HPV-associated disease at the population level.
These attributes allow us to demonstrate early impact of high HPV
immunisation coverage to show significant reductions in the
diagnosis of low- and high-grade CIN level.
MATERIALS AND METHODS
HPV surveillance cohorts. As part of the Health Protection
Scotland (HPS) HPV surveillance strategy, cohorts of young
women born between 1988 and 1992 were assessed to determine
vaccine impact. The study identification number and the patient
CHI reference (a unique national patient identifier) were sent to
Information Services Division (ISD) of the NHS in Scotland, who
used CHI to link the national Scottish Immunisation Recall System
(SIRS) and Child Health Schools Programme-System (CHSP-S)
data to screening and colposcopy attendance. This is described
more elaborately elsewhere (Kavanagh et al, 2014).
The range of ages spans the period of eligibility for vaccination
(1990–1992, i.e., the catch-up cohort) and also provides mainly
unvaccinated individuals (1988–1989) from the early cohorts, for
comparison. Geographical data-zone (Scottish Government, 2005)
derived from the postcode of residence, was attributed to each
record allowing assignment of the Scottish Index of Multiple
Deprivation (SIMD; Scottish Government) to each individual in
the cohorts.
Vaccination status derived from CHSP-S or the SIRS which act
as the call and recall register for immunisation programmes in
Scotland is linked to all individuals in the cohort.
Data linkage of the cohort. Women are referred directly by the
Scottish Cervical Call and Recall System (SCCRS) to colposcopy for
further investigation on the basis of high-grade dyskaryosis, repeat
low-grade dyskaryosis or borderline nuclear abnormality. Colpo-
scopy data are collected routinely for all referred individuals in
NHS Scotland via the National Colposcopy Clinical Information
and Audit System (NCCIAS). This information is episode based
and comprises patient demographics, appointment details, clinical
data including referral, clinical signs and symptoms, colposcopy
assessment and findings, biopsy results, cytology results, treat-
ments and the follow-up care management plan.
National Health Service ISD provided an extract of these data to
HPS, matching NCCIAS patients to the HPV surveillance cohort
via an anonymous reference number. Extracts from NCCIAS are
received by HPS on a quarterly basis, with these data in this study
based on linked referrals to the end of May 2013.
Statistical analysis. We restricted our analysis to those individuals
in the cohort with a cervical screening attendance date in SCCRS
after the age of eligibility (age 20). In the NCCIAS dataset,
individuals may have more than one linked histological episode to
the index referral cytology. We restricted our analysis to the
incident abnormal histological episode. Incidence rates per 1000
person-year (p1000py) were calculated by comparing the number
of cases of each diagnosis to the number of individuals screened,
adjusting for the person-time contribution of each individual as
those born in the early cohorts have more time to develop an
outcome. This contribution was calculated as the number of
months between the individual attending for their first screen and
the date of referral for the incident abnormal histological episode if
present (which could occur following a later screening attendance,
or alternatively to 31st May 2013 (the latest month for which
referrals were extracted), whichever occurred first. Incidence rates
p1000py were stratified by vaccination status and birth cohort.
The relative risk of CIN in the vaccinated population compared
to the unvaccinated population was calculated using Poisson
regression adjusting for cohort year to model potential changes in
sociological behaviour that may exist from one birth cohort to the
next, deprivation score (assessed via the SIMD quintiles of the area
of residence where 1 is most deprived and 5 is least deprived) and
age. Person-time contribution was used as an offset. Individuals
were censored at the date of referral for an incident abnormal
histological episode (all grades) or on 31st May 2013. As the risk
of an abnormal histological episode may change over time, age
is included as a time-dependent covariate, with person-time
contribution and the number of abnormal histological episodes
stratified by the age of the individual in months as they move
through the study. For each grade of CIN, interaction tests were
carried out to consider differences in the vaccine effect between
cohort years and between deprivation (SIMD quintile).
As a sensitivity analysis, we considered only the abnormal
histological episodes that followed the first cervical screen in only
those who attended for screening at age 20 or 21. The odds of CIN
in the vaccinated population compared to the unvaccinated
population were then calculated using logistic regression adjusting
for cohort year and deprivation score for grades CIN 1, 2 and 3
individually. This analysis considers a more homogeneous popula-
tion in terms of age and attendance for screening, and age at
histological examination. All statistical analysis was conducted in R
version 3.0.3 (Vienna, Austria) (R Development Core Team, 2014).
RESULTS
Cohort analysis. Across all five birth cohorts (n¼ 200 867), 53.5%
(n¼ 106 052) attended for their first cervical screen at age 20 or
above (Table 1). Attendance was lowest for the youngest cohort,
that is, those born in 1992 (36.3%) with these individuals having
less follow-up time at screening attendance, at the time of data
extraction. Across all five cohorts, 72% were unvaccinated and 24%
received three doses of vaccination, with vaccine uptake varying
significantly by cohort year. Ninety-nine percent of those born in
1988–1989 were unvaccinated since the programme was not
targeted at these individuals. A proportion of those born in 1990
and all of those born in 1991–1992 were eligible for vaccination.
Vaccine uptake increased yearly and was highest for the 1992
cohort where 74% of individuals received three doses (Table 1).
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The first result for an abnormal referral (this includes a result of
CIN 1 or worse) occurring after the date of first screen for each
individual was considered. Those with a date of referral prior to the
date of first screen were excluded (n¼ 10), reducing the total
cohort size from 106 052 to 106 042. Of the 10 excluded
individuals, 5 individuals had CIN 1 and were all unvaccinated,
four individuals had CIN 2, three of whom were unvaccinated and
one individual had CIN 3 who was unvaccinated. In total there
were 4854 abnormal histology (CIN 1–3) episodes; 1753 were CIN
1, 1698 CIN 2 and 1403 CIN 3 (Table 1).
Incidence and relative risk of CIN 1, 2 and 3. Incidence rates for
CIN 1, 2 and 3 diagnosis p1000py by number of vaccinations
received and birth cohort were estimated (Figure 1). For those fully
vaccinated in 1990–1992, there is a clear reduction in incidence of
CIN 3 between unvaccinated and fully vaccinated individuals, for
example, in 1991, the incidence in the unvaccinated is 7.93
p1000py (95% CI 6.13, 10.10) compared to 3.66 p1000py (95% CI
2.80, 4.69) in those receiving three doses. This reduction in
incidence of CIN 3 was statistically significant in both the
unadjusted and adjusted models (three dose unadjusted, RR 0.59,
95% CI 0.48, 0.72; Po0.0001; and three dose adjusted, RR 0.45,
95% CI 0.35, 0.58; Po0.0001; Table 2). Although those receiving
two doses of vaccine had a lower incidence rate of CIN 3 than the
unvaccinated group in the 1990–1992 cohorts, the adjusted relative
risk was not statistically significant (two dose adjusted, RR 0.77,
95% CI 0.49, 1.21; P¼ 0.25).
The adjusted analysis (Table 2) also showed a statistically
significant difference in relative risk of diagnoses of CIN 2 (RR
0.5, 95% CI 0.4, 0.63; Po0.0001) and CIN 1 (RR 0.71, 95% CI
0.58, 0.870; P¼ 0.0008) associated with three doses of vaccine
compared with those who were unvaccinated. Two doses of
vaccine were associated with a reduced risk of both CIN 2 and
CIN 1 but this was not statistically significant (CIN 2: RR 0.81,
95% CI 0.54, 1.22; P¼ 0.32 and CIN 1: RR 0.65, 95% CI 0.42, 1.01;
P¼ 0.056).
Relative risk of CIN 1, 2 and 3 diagnosis was significantly lower
for the least deprived women (SIMD 5) compared to the most
deprived (SIMD 1), even when differences in vaccination were
accounted for (Table 2). For each outcome, the relative risk of a
diagnosis was significantly lower among women from affluent
areas compared to women from very deprived areas.
Table 2 also shows that there was a significant reduction in all
grades of CIN in those born in 1989. Furthermore, for CIN 3 there
are significant reductions in those born in the 1989 and 1992
cohorts but not in those born in 1990 and 1991. Generally the
trend is downwards and conducting a test for linear trend shows
that for each of CIN 1, 2 and 3 there is a significant linear change
over the cohort years (P¼ 0.0126, Po0.0001 and P¼ 0.0009,
respectively).
Table 1. Breakdown of each birth cohort in terms of number screened and the proportion vaccinated against HPV 16 and 18 (n¼ 106052) and the
number of cervical abnormalities (CIN 1–3) found in the follow-up period (to 31st May 2013)
Attendance at cervical screening at
age X20
% of screened population
immunised
Number of cervical abnormalities
among those screened
Cohort
year
Screened
(N) Total (N)
%
screened
Unvaccinated
(%)
1 Dose
(%)
2 Doses
(%)
3 Doses
(%) CIN 1 CIN 2 CIN 3
1988 26021 41 948 62.00 99.95 0.01 0.01 0.03 638 670 559
1989 22168 40 618 54.60 99.66 0.12 0.07 0.15 449 474 378
1990 23124 39 377 58.72 82.29 1.41 2.63 13.67 375 320 276
1991 20510 39 672 51.70 31.03 3.02 6.70 59.24 217 175 151
1992 14229 39 252 36.30 18.45 2.41 5.06 74.08 74 59 39
Total 106052a 200 867 52.70 71.77 1.24 2.57 24.42 1753 1698 1403
Abbreviations: CIN¼ cervical intraepithelial neoplasia; HPV¼human papillomavirus.
aReduces to 106 042 when remove those with referral dates prior to first recorded screening date. This removed five CIN 1 (all unvaccinated), four CIN 2 (three unvaccinated, one fully
vaccinated) and one CIN 3 (unvaccinated) – CIN figures in the table are with these exclusions.
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Figure 1. Incidence rates per 1000 person-year (p1000py) and associated 95% confidence intervals of CIN 1, 2 and 3 stratified by birth cohort
and vaccination status (unvaccinated vs fully vaccinated with three doses).
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There was neither significant interaction between the number of
vaccine doses and deprivation (SIMD score) on occurrence of CIN
1, 2 or 3 (P-value of interaction tests P¼ 0.65, P¼ 0.811 and
P¼ 0.63, respectively) nor between the number of vaccine doses
and the birth cohorts (P-value of interaction tests P¼ 0.48, P¼ 0.1
and P¼ 0.86, respectively).
Sensitivity analysis. We conducted a sensitivity analysis of only
those individuals screened at age 20 or 21 and consider only
incident abnormal histology occurring within 6 months of their
first screen. This reduced our total cohort size to 91 677 of which
73% were unvaccinated and 23% fully vaccinated. Within this
reduced cohort, there were 602 CIN 1, 617 CIN 2 and 575 CIN 3
diagnoses. In adjusted analyses, women vaccinated with three
doses had a statistically significant reduced risk of being diagnosed
with CIN 1, 2 and 3 (Table 3), similar to that observed in the age-
adjusted model (Table 2) although the confidence intervals were
wider due to the smaller cohort size. As in the full model, two doses
of vaccine was associated with a reduction in each of CIN 1, 2 and
3 but this was not statistically significant (P¼ 0.176, P¼ 0.121 and
P¼ 0.352, respectively).
In this analysis, there was no significant change in the numbers
of CIN 1 and 2 by cohort year (P-values of the linear test of trend
were 0.497and 0.4463, respectively). For CIN 3, there was evidence
of a linear trend (P¼ 0.044) driven by the large reduction in the
1992 cohort coupled with marginal reductions in the preceding
birth cohorts.
DISCUSSION
In this study, we have completed a preliminary analysis of the
impact of the bivalent vaccine on HPV-associated cervical disease
at the population level. To our knowledge, this is the first
population-based study to report a statistically significant decrease
in incidence of cervical intraepithelial neoplasia grades 1, 2 and 3
(29%, 50% and 55%, respectively) in women aged 20–21, associated
with three doses of bivalent HPV vaccine administered during a
catch-up campaign.
The vaccinated women in this cohort received the HPV vaccine
through a national catch-up campaign, with mean uptake across all
age groups for all three doses recorded as 66% (NHS Information
Services Division, 2012). Since 2008, the uptake rate of the HPV
vaccine in the routine cohort (immunised at age 12–13 years) has
consistently achieved 490% (NHS Information Services Division,
2011) and therefore any effect on HPV-associated disease is likely
to be even more profound than that observed in the catch-up
cohort. These data are very encouraging for countries that have
achieved high HPV vaccine uptake.
Long-term surveillance of the effects of HPV vaccination in the
population commenced in Scotland in 2008 and incorporates the
study of both HPV prevalence in residual liquid-based cytology
samples from screening (Kavanagh et al, 2013), and the monitoring
of HPV-associated disease through national screening and
colposcopy services. Preliminary analysis of HPV prevalence in
the Scottish catch-up cohort corroborates previous studies
(Paavonen et al, 2009; Wheeler et al, 2012) and shows that the
bivalent vaccine is strongly associated with a reduction in both
HPV 16 and 18, while affording cross-protection against HPV 31,
33 and 45 (Kavanagh et al, 2014).
Our analysis focused on the risk of CIN 1, 2 and 3 dependent on
the number of doses of vaccine received adjusted for cohort year,
deprivation and age at observation. Cohort year is used to model
the possible background patterns of changes in sociological
behaviour that may exist from one birth cohort to the next. This
may influence the levels of CIN 1, 2 and 3 observed, that is, those
born in 1988 have two invitations to be screened and 3 years of
opportunistic screening between those periods, while those people
born in 1989 will not have the same screening opportunities, hence
the reduction in all grades of CIN in the 1989 cohort. In the
sensitivity analyses, which considered a more homogeneous
population, there was no significant change in the numbers of
CIN 1 and 2 by cohort year.
Although there was a significant reduction in all grades of CIN
associated with 3 doses of vaccine in this cohort, no statistically
significant reduction was observed in individuals who were
partially immunised. However, almost all of the women who
received two doses of vaccine in this cohort were immunised at
Table 3. Adjusted odds of CIN 1, 2 and 3 in the 6 months following the date of screening in those attending screening at age 20 or 21 who have 6 months
of follow-up available
OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value
CIN 1 CIN 2 CIN 3
Unvaccinated 1 — Unvaccinated 1 — Unvaccinated 1 —
1 Dose 0.92 0.45, 1.88 0.8046 0.64 0.28, 1.45 0.276 1.91 1.11, 3.29 0.0193
2 Doses 0.66 0.36, 1.20 0.1765 0.62 0.34, 1.13 0.1216 0.75 0.41, 1.36 0.3524
3 Doses 0.59 0.44, 0.79 0.0006 0.4 0.29, 0.55 o0.0001 0.5 0.36, 0.69 o0.0001
1988 1 — 1 — 1 —
1989 1 0.80, 1.25 0.9760 0.89 0.72, 1.11 0.2976 0.78 0.62, 0.98 0.0332
1990 0.91 0.72, 1.16 0.4567 0.85 0.68, 1.06 0.1552 0.92 0.74, 1.15 0.4744
1991 1.04 0.77, 1.39 0.8160 0.98 0.73, 1.31 0.8894 0.85 0.63, 1.15 0.2807
1992 1.14 0.78, 1.67 0.4737 0.79 0.52, 1.21 0.2809 0.56 0.35, 0.89 0.0143
SIMD 1 1 — 1 — 1 —
SIMD 2 0.65 0.51, 0.83 0.0005 0.77 0.62, 0.95 0.0183 0.83 0.66, 1.03 0.095
SIMD 3 0.71 0.56, 0.91 0.0074 0.53 0.41, 0.68 o0.0001 0.6 0.47, 0.78 o0.0001
SIMD 4 0.74 0.58, 0.94 0.0181 0.57 0.44, 0.73 o0.0001 0.59 0.46, 0.77 o0.0001
SIMD 5 0.66 0.52, 0.84 0.0013 0.37 0.28, 0.49 o0.0001 0.33 0.24, 0.46 o0.0001
Abbreviations: CI¼ confidence interval; CIN¼ cervical intraepithelial neoplasia; OR¼odds ratio; SIMD¼ Scottish Index of Multiple Deprivation.
Bold indicates these variables being statistically significant, that is, Po0.05.
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0 and 1 month. Further data are required to assess what protective
effect is afforded byo3 doses of vaccine since only 3.8% of women
in our cohort were partially vaccinated. We hope to elucidate the
long-term efficacy of a two-dose vaccine regimen through the
analysis of updated quarterly colposcopy extracts to the national
surveillance programme since studies suggest a two-dose regimen
may be both protective and cost-effective (Kreimer et al, 2011;
Romanowski et al, 2011).
HPV vaccination and regular cervical screening offer the
best combination for prevention of cervical cancer. However,
knowledge and awareness of HPV infection, cervical cancer and
screening in young girls who have been vaccinated against the
virus, is surprisingly low (Bowyer et al, 2013). This has prompted
concerns that those girls who have been vaccinated may not realise
they still require regular cervical screening (Marlow et al, 2007;
Henderson et al, 2011). Reassuringly, we found that there was no
reduction in the initial uptake of cervical screening in those women
who were born in 1990 and had been vaccinated in the catch-up
cohort. Nevertheless, it is imperative that health education
initiatives continue to emphasise the importance of attendance
at cervical screening for vaccinated women. This is especially
important, given the association of increased levels of HPV
positivity and poor attendance at cervical screening with increased
deprivation (O’Leary et al, 2011; Baker and Middleton, 2003).
One of the main limitations with attributing reductions in CIN to
vaccination is that women born in 1991–1992 who were fully
vaccinated, would likely have been at school up to the age of 18,
while the majority of the unvaccinated women in these cohorts
would likely have left school at age 16. Coupled with this is the
observation from a baseline prevalence study prior to vaccination
that the levels of HPV positivity among girls aged 16–18 who had
left school was much higher compared to those who were still at
school (O’Leary et al, 2011). Thus the comparison of fully vaccinated
with unvaccinated cohorts is confounded with leaving school, but no
individual adjustment can be made for this with the data available in
this study. Attributing the reduction in severe disease solely to
vaccination will overestimate the impact of the vaccination but given
that this study reports a 55% reduction in the relative risk of CIN 3
associated with three doses of vaccine, it is extremely unlikely that all
of this effect is confounded with leaving school early.
Our work builds upon previous studies that assessed high-grade
abnormalities and CIN data in both vaccinated and unvaccinated
individuals, respectively (Powell et al, 2012; Kavanagh et al, 2014;
Crowe et al, 2014; Baldur-Felskov et al, 2014). To our knowledge, this
is the first study to report vaccine effectiveness findings against
cervical lesions for the bivalent vaccine in a population rather than in
a trial setting. The strengths of our analyses are that we have a large,
complete population-based dataset on cervical screening that we can
then directly link to disease and vaccination status through use of our
national databases. Scotland is therefore in a strong position to assess
the ongoing impact of the HPV vaccine on HPV-associated disease
in the years ahead, including assessment in 2015 of vaccine impact in
the routinely immunised girls. These data are generalisable to
countries that have achieved high HPV vaccine uptake such as
Australia, Portugal and Rwanda (Hopkins and Wood, 2013). This
study highlights the gains that can be achieved if action is taken to
overcome recognised barriers to high vaccine uptake.
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